Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05708352 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
A Phase 2 study of Glioblastoma Multiforme, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 5
- Study locations
NCT05708352 is a Phase 2 study of Glioblastoma Multiforme that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 170 participants, above the 95-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (79% higher). The trial reports 5 study locations across 3 states.
The verdict
NCT05708352, a Phase 2 study of Glioblastoma Multiforme, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-site study aims to provide evidence to support the hypothesis that a Keto Diet vs. Standard Anti-Cancer Diet improves overall survival in newly diagnosed glioblastoma multiforme patients who receive standard of care treatment.
Conditions Studied
Interventions
- BEHAVIORAL Standard Anti-Cancer Diet
- BEHAVIORAL Keto Diet
Study Locations (5)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California, San Francisco - San Francisco
- Pacific Neuroscience Institute / Saint John's Cancer Institute - Santa Monica
North Carolina
- Duke University - Durham
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05708352
The ClinicalTrials.gov registry entry for NCT05708352 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 95-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (79% higher). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which Standard Anti-Cancer Diet is the first listed.
NCT05708352 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, North Carolina, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05708352 about?
NCT05708352 is a clinical study titled "A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment". This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet inter...
What is the current status of trial NCT05708352?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2023-06-27. Estimated completion is 2029-09-30.
What conditions does trial NCT05708352 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT05708352?
The interventions under investigation include: Standard Anti-Cancer Diet (BEHAVIORAL), Keto Diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT05708352?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05708352 being conducted?
This trial has 5 study locations across California, North Carolina, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.